Medication info
CandeDuo Tablets 10/16 milligrams

CandeDuo Tablets 10/16 milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Yellow round film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202107121 · Approved 2021.10.25 · Insurance code 694003680

Summary

Main use
Treatment of hypertension, heart failure, and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension, heart failure, and dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular systolic dysfunction
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take Candesartan Cilexetil and Rosuvastatin together. Candesartan Cilexetil is used in patients with essential hypertension and heart failure with impaired left ventricular function who additionally require ACE inhibitors or are intolerant to them. Rosuvastatin is used as an adjunct to diet in patients with hypercholesterolemia, mixed dyslipidemia, and familial hyperlipidemia, lowering total cholesterol and LDL cholesterol and delaying the progression of atherosclerosis. Additionally, it helps reduce the risk of stroke, myocardial infarction, and vascular reintervention in high-risk cardiovascular patients with elevated high-sensitivity C-reactive protein levels. By using these two components together, it effectively controls blood pressure and cholesterol levels, improving cardiovascular health.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause severe harm to the fetus, especially during the 2nd and 3rd trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be taken by individuals allergic to it, those with liver dysfunction, severe renal impairment, myopathy, hereditary angioedema, and other specific conditions. Women of childbearing potential must ensure proper contraception before taking this medication and should not use it if planning to become pregnant or during pregnancy. Elderly patients or those with weakened liver function should use this medication cautiously, and patients with high serum potassium levels or impaired kidney function should also be careful. This drug may cause muscle-related side effects such as myalgia, muscle weakness, or rhabdomyolysis, so if symptoms of muscle pain or weakness occur, it is essential to consult a physician immediately. Regular liver function tests and muscle enzyme (CK) tests should be performed before and during treatment, and the medication may need to be discontinued based on the findings. This medication may interact with other antihypertensives, diuretics, potassium supplements, etc., so if taking other medications, it is essential to inform healthcare providers. Care should be taken while driving or operating machinery as dizziness or fatigue may occur. Keep out of reach of children and do not transfer the medication to other containers.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, positional vertigo, miliaria, periodontitis, chest discomfort, inflammation, foreign body sensation, cataract, neck pain, musculoskeletal pain, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, weakness, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, respiratory distress, hematuria, thrombocytopenia, jaundice, hepatitis, urticaria, angioedema, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute kidney injury, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbance, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, abdominal pain, pancreatitis, myopathy, rhabdomyolysis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, sleep disturbance, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, oculobulbar weakness, hypotension, hyperkalemia, renal impairment, increased creatinine, elevated urea, increased potassium, decreased sodium, ALT elevation, dizziness, low back pain, respiratory infection, neurological and psychiatric abnormalities, low back pain, weakness, fever, paresthesia, gastroenteritis, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, respiratory distress, rash, increased sweating, hematuria, thrombocytopenia, jaundice, hepatitis, increased transaminases, rash, urticaria, angioedema, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute kidney injury, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbance, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, hypoglycemia, nephrolithiasis, cough, tooth extraction, joint pain, numbness, sensory abnormality, chest discomfort, anorexia, abdominal bloating, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow round film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.